Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005
14 Aug 2024 //
GLOBENEWSWIRE
Veralox Names Jonathan Mow as CEO as the Company Advances Development
20 Jun 2023 //
GLOBENEWSWIRE
Veralox Therapeutics Appoints Lisa Beck as Chief Business Officer
23 Feb 2022 //
PRNEWSWIRE